Marina Biotech this week released data showing that its proprietary RNAi molecules delivered with an in-house liposome delivery vehicle could be used to knock down target mRNA levels in an orthotopic model of malignant ascites.
“Malignant ascites, also known as malignancy-related ascites, is a condition in which fluid collects in the abdomen as a result of cancer,” commonly ovarian and gastrointestinal cancers, according to the company.
Intraperitoneal administration of the company's UsiRNAs targeting the oncogene polo-like kinase 1 formulated with the firm's so-called DiLA2 delivery system led to as much as 90 percent knockdown of PLK1 mRNA in ovarian cancer-derived tumor tissue through a confirmed RNAi effect.
"These results further demonstrate the utility of our DiLA2 delivery technology for local administration," Marina CSO Barry Polisky said in a statement. "As we look to expand our preclinical and clinical pipeline, malignant-related ascites is an ideal pipeline opportunity for us. ... We believe we can rapidly develop clinical candidates for IND-enabling studies should our preclinical efforts continue to demonstrate positive results."